Partners & Pipeline
Lupagen is partnered with leading biopharmaceutical and medical device companies to develop its proprietary Side CAR-T™ system, a more affordable, safer and effective CAR-T point-of-care cell therapy platform that avoids complex manufacturing and supply chain processes.
Lupagen's technology can simplify and improve a wide range of ex-vivo autologous therapies involving peripheral blood cells including lymphocytes, monocytes and hematopoietic stem cells including, but not limited to:
CAR-T cell therapies
CRISPR-Cas9 gene editing
Other non-viral based therapies
We are excited to partner with cell and gene therapy developers looking for transformative approaches to solve their development challenges, reposition their portfolio and leapfrog current products.
To join us on our mission to democratize cell and gene therapy, please visit our contact page.